
# The Emerging Stack for AI-Driven Antibody Design

### From generative language models to full end-to-end discovery pipelines

Therapeutic antibodies dominate modern biologics. Over a hundred antibody drugs are approved globally and they treat diseases ranging from cancer to autoimmune disorders. The challenge is that discovering a successful antibody is still slow, expensive, and experimentally intensive. ([PMC][1])

Traditional antibody discovery relies on immunization, phage display, or hybridoma screening. These methods work, but they explore only a tiny fraction of the possible antibody sequence space. The theoretical space of antibody sequences is astronomically large, far beyond what laboratory screening alone can search.

Artificial intelligence is now beginning to change this landscape.

In the last five years, deep learning has produced a diverse ecosystem of computational tools capable of generating antibody sequences, predicting structures, modeling antigen binding, and evaluating developability properties. These tools individually solve pieces of the antibody engineering puzzle. The real opportunity lies in **connecting them into automated pipelines** that move from antigen target to therapeutic candidate entirely in silico.

Such pipelines combine generative sequence models, structure predictors, diffusion-based protein design methods, docking algorithms, and developability predictors. When assembled correctly, they enable the design, evaluation, and optimization of antibodies in a continuous computational workflow.

This article presents a comprehensive overview of that emerging stack and describes **twenty detailed AI pipelines for antibody discovery**, illustrating how modern tools can be chained together to perform full computational antibody design.

---

# The AI Toolbox for Antibody Design

Before diving into pipelines, it helps to understand the categories of models involved. Modern antibody AI systems generally fall into four major classes:

1. **Sequence generation models**
2. **Structure prediction models**
3. **Antigen-binding design models**
4. **Developability and humanization models**

Each category solves a different part of the antibody engineering problem.

---

# Sequence Generation Models

Antibodies are defined primarily by their amino acid sequence, especially the six complementarity determining regions (CDRs) that form the antigen-binding site. Generating novel sequences that resemble functional antibodies is therefore the first step in computational design.

Recent advances in protein language models have enabled systems that learn statistical patterns from hundreds of millions of antibody sequences.

### AB-Gen

AB-Gen is a transformer model trained on tens of millions of heavy-chain CDR3 sequences from the Observed Antibody Space database. It uses reinforcement learning to bias generation toward sequences with desirable properties such as improved solubility or reduced immunogenicity.

The model focuses specifically on the CDRH3 loop, the most diverse and functionally important region of antibodies.

### AntiBERTy

AntiBERTy is a large protein language model trained on over 500 million antibody sequences. Rather than generating sequences directly, it produces high-dimensional embeddings representing antibody sequence features.

These embeddings capture patterns related to affinity maturation and binding specificity, making the model useful for clustering, ranking, and feature extraction.

### IgBERT and IgT5

These models are massive transformer architectures trained on billions of antibody sequences. Their size allows them to model the statistical landscape of antibody repertoires with high fidelity. They can predict sequence recovery, expression levels, and sometimes binding potential.

### IgLM

IgLM is an infilling language model that can complete missing regions of an antibody sequence. If a framework sequence is provided with masked CDR loops, the model generates plausible loop sequences consistent with the rest of the antibody.

### IgCraft

IgCraft represents a newer generation of antibody design models using Bayesian flow networks. It supports multiple design tasks simultaneously, including sequence generation, CDR grafting, and inverse folding.

### Diffusion models for antibody generation

Another powerful class of models uses **diffusion processes**. These models learn to generate protein structures by gradually denoising random noise into physically plausible structures.

Diffusion models are particularly useful for antibody design because they can jointly generate sequence and structure.

Examples include:

* DiffAb
* AbDiffuser
* AbX

Diffusion-based approaches have recently demonstrated the ability to generate antibody binding loops directly conditioned on antigen structure.

---

# Structure Prediction Models

Once sequences are generated, the next step is predicting the three-dimensional structure of the antibody.

Structural information is critical because antibody binding depends on precise spatial geometry between paratope and epitope.

### IgFold

IgFold is one of the fastest antibody structure predictors available. It combines embeddings from antibody language models with SE(3)-equivariant graph neural networks to predict Fv structures in seconds.

### ABodyBuilder3

ABodyBuilder3 builds on AlphaFold-style architectures and integrates language-model embeddings to improve CDR loop prediction accuracy.

Both tools provide high-quality structural predictions needed for downstream binding analysis.

---

# Antigen-Specific Antibody Design

Structure prediction alone does not guarantee antigen binding. For targeted design, models must consider the antigen.

Several emerging models incorporate antigen structure directly.

### DiffAb

DiffAb is a diffusion-based model that generates CDR sequences and structures conditioned on antigen structure.

### AbDockGen

AbDockGen uses graph neural networks to generate antibody paratopes that dock to antigen epitopes.

### RFdiffusion

RFdiffusion is currently one of the most powerful generative protein design methods. It generates entirely new protein structures that bind specific targets.

The method starts from random noise and iteratively refines structures that complement the antigen surface. ([bakerlab.org][2])

Recent work demonstrated that RFdiffusion can generate antibodies that bind target epitopes with near atomic precision. ([PMC][3])

---

# Developability and Humanization

Binding affinity alone does not make a therapeutic antibody.

Drug candidates must also be:

* stable
* soluble
* non-immunogenic
* manufacturable

### BioPhi

BioPhi provides tools for antibody humanization and humanness scoring.

Its Sapiens model suggests mutations that transform non-human antibodies into human-like sequences while preserving structure.

Other machine learning models can predict:

* aggregation propensity
* expression yield
* thermal stability

These filters ensure candidates are suitable for clinical development.

---

# The Need for Integrated Pipelines

Individually, each tool performs a specialized task. But antibody discovery requires **multiple stages**:

1. sequence generation
2. structure prediction
3. antigen binding evaluation
4. developability screening
5. optimization

AI pipelines connect these tools into workflows that perform these steps sequentially.

Below are **twenty representative pipelines**, illustrating different design strategies.

---

# Pipeline 1 — Epitope-Targeted Antibody Design

**Workflow**

RFdiffusion → ProteinMPNN → IgFold → BioPhi

This pipeline begins with the structure of an antigen epitope.

RFdiffusion generates antibody backbone structures that complement the epitope surface. Because diffusion models operate directly in structural space, they can produce entirely new antibody frameworks that fit the antigen geometry.

Next, ProteinMPNN designs sequences predicted to fold into those structures. ProteinMPNN performs inverse folding: it determines which amino acids stabilize the backbone geometry.

IgFold predicts the final antibody structure and verifies that the sequence folds correctly.

Finally, BioPhi humanizes the antibody to ensure it resembles natural human antibodies.

**Strengths**

Precise geometric targeting.

**Weakness**

Requires accurate antigen structure.

---

# Pipeline 2 — Joint Sequence-Structure Antibody Generation

**Workflow**

DiffAb → IgFold → AlphaFold-Multimer

DiffAb generates CDR loops conditioned on the antigen structure.

These loops are embedded into antibody frameworks and modeled with IgFold.

AlphaFold-Multimer then predicts the antibody-antigen complex and evaluates the binding interface.

This pipeline performs **co-design of sequence and structure simultaneously**.

---

# Pipeline 3 — CDR Loop Diversification

**Workflow**

AbDiffuser → ProteinMPNN → IgFold

Starting from a known antibody scaffold, AbDiffuser generates new CDR loops compatible with the antigen.

ProteinMPNN assigns sequences to these loops.

IgFold predicts structures and filters unstable variants.

This approach resembles computational affinity maturation.

---

# Pipeline 4 — Structure-Guided Redesign

**Workflow**

RFdiffusion → AntiFold → IgFold

RFdiffusion modifies the backbone geometry of an antibody while maintaining antigen contacts.

AntiFold then redesigns sequences to stabilize the new backbone.

IgFold validates the structural integrity.

---

# Pipeline 5 — Sequence-Only Antibody Library Generation

**Workflow**

Generative LM → AntiBERTy → IgFold → BioPhi

A generative language model produces large libraries of antibody sequences.

AntiBERTy embeddings cluster sequences and identify candidates with natural-like features.

IgFold predicts structures for selected candidates.

BioPhi ensures human-like sequences.

This pipeline prioritizes **diversity and exploration** rather than antigen specificity.

---

# Pipeline 6 — Developability-First Screening

**Workflow**

AbLang → AntiBERTy → BioPhi

This pipeline focuses on filtering large antibody datasets for developability.

AbLang corrects or fills missing sequence regions.

AntiBERTy evaluates sequence naturalness.

BioPhi evaluates humanness.

---

# Pipeline 7 — In Silico Binding Screening

**Workflow**

AntiBERTy → IgFold → AlphaFold-Multimer

Large sequence libraries are screened computationally.

AntiBERTy clusters candidates.

IgFold predicts structures.

AlphaFold-Multimer models antibody-antigen complexes.

This allows evaluation of thousands of antibodies before laboratory testing.

---

# Pipeline 8 — Affinity Maturation

**Workflow**

AntiBERTy → ProteinMPNN → IgFold

Starting from a known antibody, AntiBERTy identifies residues that may improve binding.

ProteinMPNN proposes mutations.

IgFold evaluates structural stability.

---

# Pipeline 9 — Antibody Humanization

**Workflow**

AbLang → IgFold → BioPhi

This pipeline transforms non-human antibodies into human-like sequences while preserving structure.

---

# Pipeline 10 — Inverse Folding Design

**Workflow**

ProteinMPNN → IgFold → BioPhi

ProteinMPNN designs sequences compatible with a fixed backbone scaffold.

---

# Pipeline 11 — Interface Engineering

**Workflow**

RFdiffusion → ProteinMPNN → RosettaDock

RFdiffusion designs backbone geometry at the antigen interface.

ProteinMPNN sequences the design.

RosettaDock refines binding interactions.

---

# Pipeline 12 — End-to-End Binder Discovery

**Workflow**

Generative LM → IgFold → AlphaFold-Multimer → BioPhi

This pipeline searches massive sequence space and filters candidates by structure and binding.

---

# Pipeline 13 — Epitope-Focused CDR Design

**Workflow**

DiffAb → ProteinMPNN → IgFold

DiffAb directly generates loops tailored to antigen epitopes.

---

# Pipeline 14 — Framework-Constrained Loop Generation

**Workflow**

AbDiffuser → AntiFold → IgFold

Loops are redesigned while preserving antibody framework regions.

---

# Pipeline 15 — Structural Sequence Optimization

**Workflow**

AntiFold → BioPhi → IgFold

Inverse folding improves sequence fitness for a given structure.

---

# Pipeline 16 — Hybrid Sequence and Structure Design

**Workflow**

Sequence Prompt → RFdiffusion → ProteinMPNN → IgFold

Human knowledge guides initial sequence motifs, which AI expands into full antibody structures.

---

# Pipeline 17 — Fully Integrated Discovery Pipeline

**Workflow**

RFdiffusion → ProteinMPNN → IgFold → AlphaFold-Multimer → BioPhi

This is the closest approximation of a **fully automated antibody design pipeline**.

---

# Pipeline 18 — Active Learning Antibody Design

**Workflow**

Design → Experimental testing → Retraining

AI models generate candidates, experiments evaluate them, and results retrain the models.

---

# Pipeline 19 — Manufacturability Screening

**Workflow**

AntiBERTy → Developability ML models → BioPhi

This step ensures antibodies are suitable for large-scale production.

---

# Pipeline 20 — Automated Complex Modeling

**Workflow**

DiffAb → IgFold → Docking software

This pipeline predicts antibody-antigen complexes directly.

---

# The Future of AI Antibody Discovery

The pieces for computational antibody discovery now exist.

Generative models can create antibody sequences.

Structure predictors can model folding.

Diffusion models can design binding interfaces.

Developability predictors filter viable drug candidates.

What remains is integration.

A fully automated antibody design platform could operate like this:

1. Input antigen structure
2. Generate thousands of antibodies
3. predict structures
4. simulate binding
5. filter developability
6. iterate optimization

Such systems could reduce discovery timelines dramatically.

Recent work already demonstrates that AI-designed antibodies can bind targets with near-atomic precision when combined with experimental screening. ([PMC][3])

The field is still young, but the trajectory is clear: antibody discovery is becoming increasingly computational.

The future therapeutic antibody may be discovered not in a wet lab first, but inside a neural network.
